Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation.
The long-term biochemical and clinical effectiveness of allogenic bone marrow transplantation (BMT) was shown in a severely affected, transfusion-dependent 18-month-old female with congenital erythropoietic porphyria (CEP), an autosomal recessive inborn error of heme biosynthesis resulting from mutations in the uroporphyrinogen III synthase (URO-synthase) gene. Three years post-BMT, the recipient had normal hemoglobin, markedly reduced urinary porphyrin excretion, and no cutaneous lesions with unlimited exposure to sunlight. The patient was homoallelic for a novel URO-synthase missense mutation, G188R, that expressed less than 5% of mean normal activity in Escherichia coli, consistent with her transfusion dependency. Because the clinical severity of CEP is highly variable, ranging from nonimmune hydrops fetalis to milder, later onset forms with only cutaneous lesions, the importance of genotyping newly diagnosed infants to select severely affected patients for BMT is emphasized. In addition, the long-term effectiveness of BMT in this patient provides the rationale for future hematopoietic stem cell gene therapy in severely affected patients with CEP.
Tezcan
I
I
Department of Pediatric Immunology and Hematology, Hacettepe University, Ankara, Turkey.
Xu
W
W
Gurgey
A
A
Tuncer
M
M
Cetin
M
M
Oner
C
C
Yetgin
S
S
Ersoy
F
F
Aizencang
G
G
Astrin
K H
KH
Desnick
R J
RJ
D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D009154:Mutation; D017092:Porphyria, Erythropoietic / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D012867:Skin / Q000473:pathology; D014184:Transplantation, Homologous; D014576:Uroporphyrinogen III Synthetase / Q000235:genetics
D014576:Uroporphyrinogen III Synthetase